Inhibition of ERK1/2 Restores GSK3β Activity and Protein Synthesis Levels in a Model of Tuberous Sclerosis
Abstract Tuberous sclerosis (TS) is a multi-organ autosomal dominant disorder that is best characterized by neurodevelopmental deficits and the presence of benign tumors. TS pathology is caused by mutations in tuberous sclerosis complex (TSC) genes and is associated with insulin resistance, decrease...
Guardado en:
Autores principales: | Rituraj Pal, Vitaliy V. Bondar, Carolyn J. Adamski, George G. Rodney, Marco Sardiello |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a4d9a93f97c34c3c8f582aba8a8ebcdd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Combined intermittent fasting and ERK inhibition enhance the anti-tumor effects of chemotherapy via the GSK3β-SIRT7 axis
por: Xiaolong Tang, et al.
Publicado: (2021) -
Case report on tuberous sclerosis
por: Nadezhda V. Krasnova, et al.
Publicado: (2021) -
The genomic landscape of tuberous sclerosis complex
por: Katie R. Martin, et al.
Publicado: (2017) -
Long-term undiagnosed tuberous sclerosis
por: Tatyana N. Varenova, et al.
Publicado: (2021) -
FSC231 alleviates paclitaxel‐induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK‐3β and ERK1/2
por: Xi Zhang, et al.
Publicado: (2021)